Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in on the treatment landscape for AML and the use of Vyxeos (cytarabine and daunorubicin) from Jazz Pharmaceuticals.

Ticker(s): JAZZ

Who's the expert?

Institution: Fred Hutchinson Cancer Center

Professor in the clinical research division, Endowed Chair for Cancer Research at Fred Hutchinson Cancer Center & Professor of Medicine at the University of Washington.
Currently manages over 50 patients with AML.
Research involves developing improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate AML stem cells.

Interview Goal

To better understand the treatment landscape for Acute Myeloid Leukemia (AML) with an emphasis on the current trends of Vyxeos use in clinical settings.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.